COVID-19 Funding Opportunities
The Office of the Vice Provost for Research (VPR) has compiled a list of funding opportunities specific to COVID-19. This list will be updated as new opportunities arise.
Internal Deadline: November
The Edward Mallinckrodt,
Jr. Foundation is a private foundation that funds basic biomedical research
in St. Louis and throughout the United States. The mission of the Foundation
is to support early stage investigators engaged in biomedical research
that has the potential to significantly advance the understanding, diagnosis,
or treatment of disease. Johns Hopkins is able to submit two nominations.
For more detailed information on this program, visit the Mallinckrodt
Scholars Program website.
Eligibility & Requirements:
Internal Nomination Process:
Requirements are listed below.
Questions? Comments? Email the Office of
Foundation Relations at FoundationRelations@jhu.edu.
No application deadline
The Michael J. Fox Foundation is sponsoring a $2 million prize to the first team to develop a viable selective alpha-synuclein PET tracer and agree to make that tracer available broadly.
The ability to image alpha-synuclein deposition
in the brain would be a game-changing achievement for the Parkinson's
disease (PD) field. The accumulation of aggregated alpha-synuclein is
a pathological hallmark of PD and a priority target for drug development
given its hypothesized contribution to neurodegeneration. In vivo imaging
of alpha-synuclein pathology could be useful as a biomarker of the presence
of disease and disease progression and as a pharmacodynamic tool for
drug development. With this prize, the Foundation seeks to attract research
teams and accelerate momentum to speed the development of such a tracer.
Contestants: Anyone is eligible for
the prize who agrees to all contest rules. Contestants may be MJFF funded
or not and can be from either academia or industry.
Criteria for winning: The winning contestant
must demonstrate that the radiotracer binds with relatively high selectivity
to alpha-synuclein according to pre-specified criteria and must demonstrate
proof-of-concept in human subjects, including people with Parkinson's
disease and/or another synucleinopathy. See below for more details on
Timeline: There is no deadline
for submissions. The $2 million award will be issued to the first
contestant who submits compelling evidence of a viable selective tracer
and agrees to its widespread use.